Three ASX companies jockeying to be the next biotech winners

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 40 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 90%

Deutschland Nachrichten Nachrichten

Deutschland Neuesten Nachrichten,Deutschland Schlagzeilen

Clarity Pharmaceuticals reports it eliminated prostate cancer in a patient; LTR Pharma wants to sell nasal viagra; and Opthea has clinical trial results soon.

To make blockbuster returns in the sharemarket, you’ve got to find the winners of tomorrow, not today.

Clarity Pharmaceuticals is a radiopharmaceuticals medical group which uses radiation to target cancers for diagnostic and treatment purposes. Its product offers radiation against cancer cells by injecting radioisotopes named Cu-64 and Cu-67 into a patient, with its targeted nature meaning it tends to have less chronic side effects than the current standard of care chemotherapy.

Excitement around LTR stock has seen it quadruple in value since its December 2023 IPO and management says its product, named Spontan, works faster as it’s inhaled as a nasal spray, so it gets into the bloodstream quicker. But even if it does get approval, it will face a hard slog selling its product against generic competition that retails for just $13.99 a dose at Chemist Warehouse.

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

 /  🏆 2. in DE
 

Vielen Dank für Ihren Kommentar.Ihr Kommentar wird nach Prüfung veröffentlicht.

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

ASX 200 LIVE: ASX to drop, megacap tech earnings in focusShares are poised to drop 0.8 per cent at the start of trade; Biden exit leaves markets asking what’s next for ‘Trump trade’; Alphabet and Tesla report this week. Follow here more.
Herkunft: FinancialReview - 🏆 2. / 90 Weiterlesen »